Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq

IPO/OfferingPositive

AI Analysis

Summary

Attovia Therapeutics, a clinical-stage biopharmaceutical company focused on immune-mediated diseases, successfully completed its initial public offering on Nasdaq under ticker ATTO on August 5, 2026, pricing shares at $17.00.

Outcome Details

Successfully listed on Nasdaq at $17.00 per share

Importance:7/10

Sentiment:

0.70

IPONasdaqImmune-mediated diseaseClinical-stageBiopharmaceutical

Related Companies

$ATTO

Read the original article

Published by PR Newswire Pharma on August 6, 2026 10:23 AM

Read Original